Neumedicines Inc. To Feature HemaMax Study Results In Presentation At Biotech Showcase Conference
1/9/2014 9:58:37 AM
Neumedicines Inc., a privately held company developing therapies based on interleukin 12 (IL-12) as a radiation medical countermeasure and as a hematopoietic immunotherapeutic (HIT), today announced that Neumedicines President & CEO Lena A. Basile, Ph.D., J.D., will present at the Biotech Showcase™ conference on Wednesday, January 15, at 11:30 a.m. The conference is being held at the Parc 55 Wyndham hotel in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
comments powered by